Royal Flying Doctor Service Endorses EMVision’s First Responder Device
EMVision Medical Devices (ASX:EMV) has received positive feedback from the Royal Flying Doctor Service (RFDS) regarding its portable stroke detection device, the First Responder. The device was tested in challenging environments, proving to be user-friendly and effective in aeromedical transfers.
The RFDS conducted a formal study involving 17 adult participants undergoing aeromedical medivac. The device was deployed on 15 transfers across 12 airstrips, some as far as 371km from Adelaide Airport. Medics carried out scans in various settings, including on the tarmac, stationary aircraft, and in clinics. The results showed that the First Responder can be “deployed and operated effectively across a range of real-world environments.”
Users rated the device highly for patient setup, device preparation, and scanner operation. Ninety-two percent of users felt calm during the scan, and all expressed willingness for the device to be used on a family member. The median scan time was five minutes and seven seconds, with the expectation that production-equivalent devices will significantly reduce this time.
Enhancing Stroke Detection in Remote Areas
First Responder is designed to address the challenges faced by rural and remote patients who often have to wait longer for stroke imaging. The device helps medics quickly determine whether a stroke is ischaemic or haemorrhagic, which directly influences treatment decisions.
EMVision notes that the findings suggest the device is intuitive, practical, and well-suited to the aeromedical environment. The company is progressing to equivalent commercial units, which will support upcoming data collection, diagnostic performance testing, and regulatory clearance.
A separate mobile stroke unit study is also evaluating the First Responder in similar real-world conditions. Additionally, preparations are underway for a study assessing the device in a standard road ambulance.
Neurizon Therapeutics Achieves Key Milestones
Neurizon Therapeutics (ASX:NUZ) is making progress in its key ALS trial, expanding the patient cohort while flagging an accelerated topline readout. The phase II/III Healey ALS trial is part of a US multi-study effort, and the expansion from 160 to 240 participants will maintain statistical power for the primary endpoint.
The trial involves 64 US clinical sites, with 74 out of 113 participants dosed as of last Friday. Neurizon expects the last participant to be dosed in the June quarter next year, with top-line results expected in the September quarter. The cost of additional patients is offset by a philanthropic contribution from the Sean M. Healey & AMG Center for ALS at Mass General Brigham.
Cynata Announces Upcoming Trial Results
Cynata Therapeutics (ASX:CYP) is set to reveal results from two late-stage clinical trials next month. The most advanced is the phase III knee osteoarthritis trial, Sculptor 3, which enrolled 321 patients. The trial, funded by the National Health and Medical Research Council, is expected to release data in June 2026.
In phase II, a global trial for graft-versus-host disease is nearing completion, with results expected in late June or early July. Cynata’s therapies, CYP-004 and CYP-001, are based on its Cymerus platform, which uses induced pluripotent stem cells to overcome limitations in conventional mesenchymal stem cell production.
Cryosite Reports Strong Performance
Cryosite (ASX:CTE) reported strong financial results for the 10 months to April, with revenue growing 22% to $13.8m and EBITDA up 28% to $3.4m. The company attributes this growth to increased use of its expanded facility in Sydney’s South Granville, driven by rising global clinical trial activity.
April was a record month for EBITDA, with core storage, inbound, and outbound service revenues remaining the primary drivers of performance. Operational volumes in May 2026 indicate continued momentum, supported by demand for ultra-frozen and cryogenic services.
Recce Pharmaceuticals Secures Major Deal
Recce Pharmaceuticals (ASX:RCE) has signed a non-binding 10-year deal with a leading Middle Eastern pharmaceutical company. The agreement includes an upfront signing fee, milestone payments of up to US$3.5m, and a 30% share of net selling price. Recce will also receive a 6% annual royalty on net sales exceeding US$50m a year.
The deal relates to Recce’s R327G topical gel, targeting diabetic foot infections and currently in phase III trials in Indonesia. Post-approval, the proposed selling price per treatment is US$1500. The exclusive agreement covers Saudi Arabia, Gulf Cooperation Council countries, and Egypt.
